Canada markets closed

Sophiris Bio, Inc. (SPHS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0100-0.0012 (-10.71%)
At close: 3:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0112
Bid0.0000 x 2200
Ask0.0000 x 800
Day's Range0.0100 - 0.0112
52 Week Range0.0100 - 1.0700
Avg. Volume611,857
Market Cap344,721
Beta (5Y Monthly)N/A
PE Ratio (TTM)10.00
Earnings DateNov. 09, 2018 - Nov. 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.75
  • GlobeNewswire

    Sophiris Bio Announces Nasdaq Delisting

    Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that on March 10, 2020, the Nasdaq Office of General Counsel notified the Company that the Nasdaq Hearing Panel (“Panel”) had determined to delist the Company’s shares from The Nasdaq Stock Market LLC (“Nasdaq”), and that trading in the Company’s common shares will be suspended effective at the open of business on March 12, 2020. Nasdaq will thereafter file a Form 25 with the Securities and Exchange Commission (“SEC”) to effect the formal delisting of the Company’s common stock following the expiration of all applicable Nasdaq procedures.

  • GlobeNewswire

    Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia, Nov. 07, 2019 -- Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class,.